Role of guanylate cyclase modulators in decompensated heart failure

Heart Failure Reviews

Volumn 14, Issue 4, 2009, Pages 309-319

  Mitrovic, Veselin ^a   Hernandez, Adrian F ^b   Meyer, Markus ^c   Gheorghiade, Mihai ^d  

^a KERCKHOFF HEART CENTER   (Germany)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Focus IP GmbH   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cinaciguat; Cyclic guanosine monophosphate (cGMP); Decompensated heart failure; Guanylate cyclase; Ularitide

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM SENSITIZER; CARDIOVASCULAR AGENT; CFM 1571; DIGOXIN; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; GUANYLATE CYCLASE MODULATOR; HMR 1766; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NESIRITIDE; NITRIC OXIDE; PLACEBO; RIOCIGUAT; UNCLASSIFIED DRUG; URODILATIN; VASODILATOR AGENT;

ACUTE HEART FAILURE; BLOOD PRESSURE REGULATION; CHRONOTROPISM; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; HYPOTENSION; INOTROPISM; KIDNEY FUNCTION; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SYMPTOM; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BENZOIC ACIDS; CREATININE; DISEASE PROGRESSION; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; HEART FAILURE; HEMODYNAMICS; HUMANS; INFUSIONS, INTRAVENOUS; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PEPTIDE FRAGMENTS;

EID: 70449519147     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-009-9149-7     Document Type: Review

References (66)

1. J Fang GA Mensah JB Croft NL Keenan 2008 Heart failure-related hospitalization in the U.S., 1979 to 2004 J Am Coll Cardiol 52 428 434 10.1016/j.jacc.2008.03.061 18672162 (Pubitemid 352040814)
2. P Pacher JS Beckman L Liaudet 2007 Nitric oxide and peroxynitrite in health and disease Physiol Rev 87 315 424 10.1152/physrev.00029.2006 17237348 (Pubitemid 46217686)
3. P Pacher R Schulz L Liaudet C Szabo 2005 Nitrosative stress and pharmacological modulation of heart failure Trends Pharmacol Sci 26 302 310 10.1016/j.tips.2005.04.003 15925705 (Pubitemid 40733523)
4. DJ Wang TC Dowling D Meadows T Ayala J Marshall S Minshall N Greenberg E Thattassery ML Fisher K Rao SS Gottlieb 2004 Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine Circulation 110 1620 1625 10.1161/01.CIR.0000141829.04031.25 15337695 (Pubitemid 39297985)
5. LA Allen CM O'Connor 2007 Management of acute decompensated heart failure CMAJ 176 797 805 17353535
6. K Dickstein A Cohen-Solal G Filippatos JJ McMurray P Ponikowski PA Poole-Wilson A Stromberg DJ van Veldhuisen D Atar AW Hoes A Keren A Mebazaa M Nieminen SG Priori K Swedberg A Vahanian J Camm R De Caterina V Dean C Funck-Brentano I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2388 2442 10.1093/eurheartj/ehn309 18799522
7. S Iyengar WT Abraham 2007 Diuretics for the treatment of acute decompensated heart failure Heart Fail Rev 12 125 130 10.1007/s10741-007-9015-4 17447138 (Pubitemid 46916958)
8. BF McBride CM White 2003 Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management Pharmacotherapy 23 997 1020 10.1592/phco.23.8.997.32873 12921247 (Pubitemid 36904001)
9. A Mebazaa MS Nieminen M Packer A Cohen-Solal FX Kleber SJ Pocock R Thakkar RJ Padley P Poder M Kivikko 2007 Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial JAMA 297 1883 1891 10.1001/jama.297.17.1883 17473298 (Pubitemid 46707842)
10. JD Sackner-Bernstein HA Skopicki KD Aaronson 2005 Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 1487 1491 10.1161/01.CIR.0000159340.93220.E4 15781736 (Pubitemid 40470642)
11. WT Abraham KF Adams GC Fonarow MR Costanzo RL Berkowitz TH LeJemtel ML Cheng J Wynne 2005 In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46 57 64 10.1016/j.jacc.2005.03.051 15992636 (Pubitemid 40905130)
12. JN Cohn SO Goldstein BH Greenberg BH Lorell RC Bourge BE Jaski SO Gottlieb F McGrew III DL DeMets BG White 1998 A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators N Engl J Med 339 1810 1816 10.1056/NEJM199812173392503 9854116 (Pubitemid 29005785)
13. GM Felker CM O'Connor 2001 Rational use of inotropic therapy in heart failure Curr Cardiol Rep 3 108 113 10.1007/s11886-001-0035-8 11177666
14. M Gheorghiade D Benatar MA Konstam CA Stoukides RO Bonow 1997 Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials Am J Cardiol 80 14H 27H 10.1016/S0002-9149(97)00816-3 9372994 (Pubitemid 27515239)
15. M Domanski J Norman B Pitt M Haigney S Hanlon E Peyster 2003 Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD) J Am Coll Cardiol 42 705 708 10.1016/S0735-1097(03)00765-4 12932605 (Pubitemid 37000189)
16. KA Lucas GM Pitari S Kazerounian I Ruiz-Stewart J Park S Schulz KP Chepenik SA Waldman 2000 Guanylyl cyclases and signaling by cyclic GMP Pharmacol Rev 52 375 414 10977868
17. B Kemp-Harper R Feil 2008 Meeting report: cGMP matters Sci Signal 1 pe12 10.1126/stke.19pe12 18319447
18. OV Evgenov P Pacher PM Schmidt G Hasko HH Schmidt JP Stasch 2006 NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential Nat Rev Drug Discov 5 755 768 10.1038/nrd2038 16955067 (Pubitemid 44323702)
19. J Su PM Scholz HR Weiss 2005 Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes Exp Biol Med (Maywood) 230 4 242 250
20. EH Rho WJ Perkins RR Lorenz DO Warner KA Jones 2002 Differential effects of soluble and particulate guanylyl cyclase on Ca(2+) sensitivity in airway smooth muscle J Appl Physiol 92 257 263 11744668
21. O Zolle AM Lawrie AW Simpson 2000 Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP J Biol Chem 275 25892 25899 10.1074/jbc.M000786200 10851228 (Pubitemid 30676625)
22. CY Lee JC Burnett Jr 2007 Natriuretic peptides and therapeutic applications Heart Fail Rev 12 131 142 10.1007/s10741-007-9016-3 17440808 (Pubitemid 46916959)
23. Boerrigter G, Lapp H, Burnett JC (2009) Modulation of cGMP in heart failure: a new therapeutic paradigm. In: Schmidt HHHW et al (eds) cGMP: generators, effectors and therapeutic implications. Handbook of experimental pharmacology, vol 191. Springer-Verlag, Berlin and Heidelberg, pp 485-507
24. D de Zeeuw WM Janssen PE de Jong 1992 Atrial natriuretic factor: its (patho)physiological significance in humans Kidney Int 41 1115 1133 10.1038/ki.1992.172 1319517
25. SP D'Souza M Davis GF Baxter 2004 Autocrine and paracrine actions of natriuretic peptides in the heart Pharmacol Ther 101 113 129 10.1016/j.pharmthera.2003.11.001 14761702 (Pubitemid 38167564)
26. DL Vesely JR Dietz JR Parks EA Antwi RM Overton MT McCormick G Cintron DD Schocken 1999 Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure Am Heart J 138 625 632 10.1016/S0002-8703(99)70175-4 10502206 (Pubitemid 29471035)
27. SA Atlas T Maack 1987 Effects of atrial natriuretic factor on the kidney and the renin-angiotensin-aldosterone system Endocrinol Metab Clin North Am 16 107 143 2962862 (Pubitemid 18088765)
28. K van der Zander AJ Houben L Hofstra AA Kroon PW de Leeuw 2003 Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study Am J Physiol Heart Circ Physiol 285 H1206 H1212 12738624
29. RA Rose WR Giles 2008 Natriuretic peptide C receptor signalling in the heart and vasculature J Physiol 586 353 366 10.1113/jphysiol.2007.144253 18006579
30. T Suzuki T Yamazaki Y Yazaki 2001 The role of the natriuretic peptides in the cardiovascular system Cardiovasc Res 51 489 494 10.1016/S0008-6363(01) 00238-3 11476739 (Pubitemid 32718597)
31. HH Chen 2007 Heart failure: a state of brain natriuretic peptide deficiency or resistance or both! J Am Coll Cardiol 49 1089 1091 10.1016/j.jacc.2006.12.013 17349889 (Pubitemid 46389361)
32. RM Mills TH LeJemtel DP Horton C Liang R Lang MA Silver C Lui K Chatterjee 1999 Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group J Am Coll Cardiol 34 155 162 10.1016/S0735-1097(99)00184-9 10400005
33. SJ Holmes EA Espiner AM Richards TG Yandle C Frampton 1993 Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man J Clin Endocrinol Metab 76 91 96 10.1210/jc.76.1.91 8380606 (Pubitemid 23027559)
34. M Yoshimura H Yasue E Morita N Sakaino M Jougasaki M Kurose M Mukoyama Y Saito K Nakao H Imura 1991 Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure Circulation 84 1581 1588 1914098
35. KT Jensen H Eiskjaer J Carstens EB Pedersen 1999 Renal effects of brain natriuretic peptide in patients with congestive heart failure Clin Sci (Lond) 96 5 15 10.1042/CS19980105 (Pubitemid 29045859)
36. C Drummer M Kentsch W Otter M Heer M Herten R Gerzer 1997 Increased renal natriuretic peptide (urodilatin) excretion in heart failure patients Eur J Med Res 2 347 354 9262488
37. M Meyer R Richter R Brunkhorst E Wrenger P Schulz-Knappe A Kist P Mentz EG Brabant KM Koch G Rechkemmer WG Forssmann 1996 Urodilatin is involved in sodium homeostasis and exerts sodium-state-dependent natriuretic and diuretic effects Am J Physiol 271 3 Pt 2 F489 F497 8853410
38. V Mitrovic PM Seferovic D Simeunovic AD Ristic M Miric VS Moiseyev Z Kobalava K Nitsche WG Forssmann H Luss M Meyer 2006 Haemodynamic and clinical effects of ularitide in decompensated heart failure Eur Heart J 27 2823 2832 10.1093/eurheartj/ehl337 17074775 (Pubitemid 44871466)
39. V Mitrovic H Luss K Nitsche K Forssmann E Maronde K Fricke WG Forssmann M Meyer 2005 Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial Am Heart J 150 1239 10.1016/j.ahj.2005.01.022 16338265 (Pubitemid 41773529)
40. Publication Committee for the VMAC Investigators 2002 Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial JAMA 287 1531 1540 10.1001/jama.287.12. 1531
41. JD Sackner-Bernstein M Kowalski M Fox K Aaronson 2005 Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 1900 1905 10.1001/jama.293.15. 1900 15840865 (Pubitemid 40548187)
42. CW Yancy H Krum BM Massie MA Silver LW Stevenson M Cheng SS Kim R Evans for the FUSION II Investigators 2008 Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the second follow-up serial infusions of nesiritide (FUSION II) trial Circ Heart Fail 1 9 16 10.1161/CIRCHEARTFAILURE.108.767483 19808265
43. RM Mentzer Jr MC Oz RN Sladen AH Graeve RF Hebeler Jr JM Luber Jr NG Smedira 2007 Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial J Am Coll Cardiol 49 716 726 10.1016/j.jacc.2006.10.048 17291938 (Pubitemid 46205038)
44. AF Hernandez CM O'Connor RC Starling CJ Reist PW Armstrong K Dickstein TJ Lorenz WB Gibler V Hasselblad M Komajda B Massie JJ McMurray M Nieminen JL Rouleau K Swedberg RM Califf 2009 Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) Am Heart J 157 271 277 10.1016/j.ahj.2008.07.031 19185633
45. J Carstens KT Jensen EB Pedersen 1998 Metabolism and action of urodilatin infusion in healthy volunteers Clin Pharmacol Ther 64 73 86 10.1016/S0009-9236(98)90025-X 9695722 (Pubitemid 28377333)
46. KV Liang AW Williams EL Greene MM Redfield 2008 Acute decompensated heart failure and the cardiorenal syndrome Crit Care Med 36 S75 S88 10.1097/01.CCM.0000296270.41256.5C 18158481
47. MH Bestle NV Olsen P Christensen BV Jensen P Bie 1999 Cardiovascular, endocrine, and renal effects of urodilatin in normal humans Am J Physiol 276 R684 R695 10070128
48. H Luss V Mitrovic PM Seferovic D Simeunovic AD Ristic VS Moiseyev WG Forssmann AM Hamdy M Meyer 2008 Renal effects of ularitide in patients with decompensated heart failure Am Heart J 155 1012.e1 1012.e8 10.1016/j.ahj.2008. 02.011 (Pubitemid 351721023)
49. M Kentsch D Ludwig C Drummer R Gerzer G Muller-Esch 1992 Haemodynamic and renal effects of urodilatin in healthy volunteers Eur J Clin Invest 22 319 325 10.1111/j.1365-2362.1992.tb01469.x 1317296
50. SS Gottlieb W Abraham J Butler DE Forman E Loh BM Massie CM O'Connor MW Rich LW Stevenson J Young HM Krumholz 2002 The prognostic importance of different definitions of worsening renal function in congestive heart failure J Card Fail 8 136 141 10.1054/jcaf.2002.125289 12140805 (Pubitemid 34857278)
51. M Packer WH Lee PD Kessler SS Gottlieb N Medina M Yushak 1987 Prevention and reversal of nitrate tolerance in patients with congestive heart failure N Engl J Med 317 799 804 3114637 (Pubitemid 17136471)
52. J Foerster C Harteneck J Malkewitz G Schultz D Koesling 1996 A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits Eur J Biochem 240 380 386 10.1111/j.1432-1033.1996. 0380h.x 8841402
53. LJ Ignarro JB Adams PM Horwitz KS Wood 1986 Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms J Biol Chem 261 4997 5002 2870064
54. R Feil B Kemp-Harper 2006 cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications EMBO Rep 7 149 153 10.1038/sj.embor.7400627 16439998
55. HHHW Schmidt PM Schmidt JP Stasch 2009 NO- and haem-independent soluble guanylate cyclase activators Handb Exp Pharmacol 191 313 341
56. JP Stasch P Schmidt C Alonso-Alija H Apeler K Dembowsky M Haerter M Heil T Minuth E Perzborn U Pleiss M Schramm W Schroeder H Schroder E Stahl W Steinke F Wunder 2002 NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle Br J Pharmacol 136 773 783 10.1038/sj.bjp.0704778 12086987
57. P Schmidt M Schramm H Schroder JP Stasch 2003 Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase Eur J Pharmacol 468 167 174 10.1016/S0014-2999(03)01674-1 12754054 (Pubitemid 36712896)
58. PM Schmidt M Schramm H Schroder F Wunder JP Stasch 2004 Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase J Biol Chem 279 3025 3032 10.1074/jbc.M310141200 14570894 (Pubitemid 38114295)
59. JP Stasch PM Schmidt PI Nedvetsky TY Nedvetskaya H Sa S Meurer M Deile A Taye A Knorr H Lapp H Muller Y Turgay C Rothkegel A Tersteegen B Kemp-Harper W Muller-Esterl HH Schmidt 2006 Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels J Clin Invest 116 2552 2561 10.1172/JCI28371 16955146 (Pubitemid 44330154)
60. H Lapp V Mitrovic N Franz H Heuer M Buerke J Wolfertz W Mück S Unger G Wensing R Frey 2007 BAY 58-2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile BMC Pharmacology 7 S9 10.1186/1471-2210-7-S1-S9
61. G Boerrigter LC Costello-Boerrigter A Cataliotti H Lapp JP Stasch JC Burnett Jr 2007 Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure Hypertension 49 1128 1133 10.1161/HYPERTENSIONAHA. 106.083832 17325237 (Pubitemid 351664312)
62. G Boerrigter LC Costello-Boerrigter A Cataliotti H Lapp JP Stasch JC Burnett Jr 2007 Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure BMC Pharmacology 7 P9 10.1186/1471-2210-7- S1-P9
63. R Frey W Muck S Unger U Artmeier-Brandt G Weimann G Wensing 2008 Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers J Clin Pharmacol 48 1400 1410 10.1177/0091270008322906 18779378
64. Mitrovic V, Lapp H, Franz N, Heuer H, Buerke M, Wolfertz J, Mück W, Unger S, Wensing G, Frey R (2008) The soluble guanylate cyclase activator cinaciguat (BAY 58-2667) has a favourable safety profile and improves cardiopulmonary haemodynamics in acute decompensated heart failure. Poster presented at Heart Failure 2008, 14-17 June, Milan, Italy
65. H Lapp V Mitrovic N Franz H Heuer M Buerke J Wolfertz W Mueck S Unger G Wensing R Frey, et al. 2009 Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure Circulation 119 2781 2788 10.1161/CIRCULATIONAHA.108.800292 19451356
66. G Boerrigter JC Jr Burnett 2009 Soluble guanylate cyclase: not a dull enzyme Circulation 119 2752 2754 10.1161/CIRCULATIONAHA.109.860288 19451346